Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 1
2(40.0%)
5Total
N/A(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03157323Not ApplicableActive Not Recruiting

Low GI Diet in Children and Adolescents With ALL

Role: collaborator

NCT01898793Phase 1Terminated

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Role: collaborator

NCT02708108Not ApplicableCompleted

Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)

Role: collaborator

NCT02273102Phase 1Completed

Study of TCP-ATRA for Adult Patients With AML and MDS

Role: collaborator

NCT01010230Not ApplicableCompleted

Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors

Role: collaborator

All 5 trials loaded